The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases characterized by muscle weakness and extramuscular manifestations such as skin rashes and interstitial lung disease. We genotyped 2,566 IIM cases of Caucasian descent using the Immunochip; a custom array covering 186 established autoimmune susceptibility loci. The cohort was predominantly comprised of dermatomyositis (DM, n=879), juvenile dermatomyositis (JDM, n=481), polymyositis (PM, n=931) and inclusion body myositis (IBM, n=252) patients collected from 14 countries through the Myositis Genetics Consortium. The human leukocyte antigen (HLA) and PTPN22 regions reached genome-wide significance (p<5×10 −8 ). Nine regions were associated at a significance level of p<2.25×10 −5 , including UBE2L3, CD28 and TRAF6, with evidence of independent effects within STAT4. Analysis of clinical subgroups revealed distinct differences between PM, and DM and JDM. PTPN22 was associated at genome-wide significance with PM, but not DM and JDM, suggesting this effect is driven by PM. Additional suggestive associations including IL18R1 and RGS1 in PM and GSDMB in DM were identified. HLA imputation confirmed that alleles HLA-DRB1*03:01 and HLA-B*08:01 of the 8.1 ancestral haplotype (8.1AH) are most strongly associated with IIM, and provides evidence that amino acids within the HLA, such as HLA-DQB1 position 57 in DM, may explain part of the risk in this locus.
Introduction
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases, the major phenotypes of which are dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and DM/PM overlapping with other connective tissue diseases. [1] IIM are primarily characterised by the presence of proximal muscle weakness, elevated levels of skeletal muscle enzymes and inflammatory infiltrates in skeletal muscle, but may also present with extramuscular manifestations including skin rashes, interstitial lung disease and malignancy that often correlate with serum antibody status. [2] IIM are thought to be complex genetic diseases, initiated by immune activation following specific environmental events in genetically predisposed individuals. The strongest genetic association in the IIM has been consistently within the major histocompatibility complex (MHC), [3] specifically with the 8.1 ancestral haplotype (8.1 AH). A recent genome-wide association study (GWAS) in DM, and a candidate gene study, also indicate overlap of genes implicated in other autoimmune diseases. [4, 5] The Immunochip is a custom-designed array containing coverage of 186 established autoimmune susceptibility loci and extended coverage across the MHC. [6] In this study, we report an Immunochip analysis of 2,566 global IIM cases and 15,651 controls, representing the largest genetic association study to date in IIM.
Methods

Samples
2,954 samples from 14 countries were collected through the Myositis Genetics Consortium (MYOGEN), and written informed consent was obtained from all cases with approval from research ethics boards at each participating centre. There is overlap between these samples and previous IIM genetic studies. [3] [4] [5] IIM cases were included if they fulfilled probable or definite Bohan and Peter classification criteria for PM, juvenile PM (JPM), DM or Juvenile DM (JDM), [7, 8] and Griggs or European Neuromuscular Centre (ENMC) or Medical Research Council (MRC) criteria for IBM. [9] [10] [11] Eleven samples met the criteria for antisynthetase syndrome, [12] however available clinical data was not able to differentiate between PM or DM. These were included in the combined IIM analysis, but removed from the clinical subgroup analysis.
Immunochip control data from 12 countries was provided by four disease consortia (online supplementary methods).
Statistical Analysis
Statistical analysis was performed in PLINK v1.07 using a logistic regression applying an additive model, including the top ten principal components as covariates to control for population stratification. Evidence for additional independent effects was investigated using a stepwise logistic regression including the most associated variants as covariates in subsequent conditional analyses.
Functional annotation
Associated loci were interrogated for potentially causative variants using eQTL databases, and the functional prediction tools PolyPhen-2, [13] SIFT, [14] and phastCons17-way [15] (online supplementary methods).
MHC imputation and association analysis
Classical human leukocyte antigen (HLA) alleles and corresponding amino acid sequences were imputed using SNP2HLA. A logistic regression assuming an additive model was used to test for association, and forward stepwise logistic regression was used to test for independent effects (online supplementary methods). Classical 4-digit HLA alleles were preferentially reported, unless an amino acid association explained more risk than HLA alleles alone.
Results
Genotyping quality control
After stringent SNP and sample quality control we analysed 90,536 genetic variants in 2,566 IIM cases and 15,651 controls of Caucasian descent (Table 1) . A breakdown of this cohort by clinical subgroup is reported in Table S1 . Australia, Denmark and Switzerland did not have an ethnically matched control group; however, these were adequately matched by existing cohorts (UK, Sweden, and Germany respectively). By including the top ten principal components as covariates and calculating the genomic inflation on a set of null SNPs (from a study investigating the genetic basis for reading and writing ability) [16] on the Immunochip gave a λGC 1000 = 1.05, indicating that cases and controls are well matched for ethnicity (online supplementary Figure S1 ).
HLA and PTPN22 are the most strongly associated regions in IIM Two regions in this study reached genome-wide significance (p<5×10 −8 ) ( Figure 1A and Table 2 ). As expected, the most strongly associated region was within the MHC (p=9×10 −133 ) (online supplementary Figure S2 ). HLA-imputation was performed separately on this locus.
The other region reaching genome-wide significance was within the PTPN22 locus (rs2476601; p=7.22×10 −9 ), an established autoimmune risk locus. This SNP/locus has been previously associated in an IIM candidate gene study, [3] but was not associated in a GWAS in DM. [4] A further nine regions were associated at a suggestive level of significance We next investigated associations reaching our suggestive tier of association (p=2.25×10 −5 ) calculated using the genetic Type 1 Error Calculator. [31] This estimates the effective number of independent tests based on the LD between SNPs contained on the genotyping array. Here, we found evidence of a further nine associated loci ( Table 2 ).
The third most strongly associated SNP in this analysis was in the YDJC gene (rs5754467) on chromosome 22 (4.67×10 −7 ). This SNP tags a large haplotype block containing UBE2L3, an established autoimmune risk locus.
STAT4 is a susceptibility locus for many autoimmune diseases. The lead SNP in this region was protective, which is a novel finding in IIM (rs4853540, p=1.57×10 −6 ). Stepwise logistic regression analysis in this region suggested an independent risk effect of rs10174238 (p=1.08×10 −5 , OR=1.17, 95% CI=1.09-1.26) (online supplementary Figure S3 ) and a further potential independent effect was seen at rs932169 (p=2.88×10 −5 , OR=1.25, 95% CI=1.13-1.39).
Further variants reaching our suggestive significance threshold reveal loci of interest that have been previously associated with autoimmune disease, including DGKQ, EOMES, CD28 and PRR5L/TRAF6. Associated SNPs that tag risk haplotypes (r2 >0.7) in other autoimmune diseases are reported in Table 2 , and the direction of effect is reported in online supplementary Table S2 .
Subgroup analysis reveals unique associations within PM and DM
We stratified our cohort by the two largest subgroups within IIM, consisting of 931 adult PM cases ( Figure 1B , Table 2 ) and 1,360 DM cases ( Figure 1C , Table 2 ). JDM cases were included in the DM analysis both to increase power, and on previous evidence that there is not extensive genetic heterogeneity between the subgroups. [4] The only non-HLA region to reach genome-wide significance in either subgroup was PTPN22 in PM (rs2476601, p=7.9×10 −11 ). Interestingly, with a smaller sample size, the association in PM with PTPN22 was stronger than in the combined IIM analysis. There was no evidence of association in DM (p=0.19), therefore the stronger effect in PM appears to be driving the association in the combined IIM analysis. Other interesting regions reaching a suggestive level of significance were SL26A1/IDUA and RGS1 in PM, and GSDMB in DM (online supplementary Table   S3 ).
Exonic and eQTL SNPs suggest potential causal variants
Potential functionally relevant variants were investigated for non-synonymous SNPs (Table  3) or eQTLs ( Table 4) that are tagged by the lead SNP (r 2 > 0.9). Two variants within the GSDMB gene, suggestively associated in DM, are 'potentially damaging' as predicted by PolyPhen-2. The PTPN22 variant is confirmed to be conserved across vertebrates, as well as a SNP in UBE3B. Evidence for eQTLs in cells with immune function (lymphoblastoid cell lines and monocytes) was found in six loci and may help annotate our associations, for example, the association with NAB1 in PM may be due to an eQTL affecting the expression of STAT1, 275Kb upstream.
HLA Imputation confirms alleles of the 8.1 ancestral haplotype as the strongest association in IIM
Due to the complex linkage disequilibrium/haplotype structure in the MHC, interpretation of causal associations and independent effects using SNPs may be inadequate. We used SNP2HLA to impute classical HLA alleles and amino acids from SNP genotyping information. For each analysis, all variants reaching statistical significance (p<6.8×10 −6 ) after each round of conditioning are included in online supplementary Table S4-S15. For many associations, amino acids unique to classical HLA risk alleles were associated at similar levels of significance to the HLA allele. For consistency, 4-digit HLA alleles are reported, unless an amino acid is significantly more associated than individual HLA alleles. In the combined IIM analysis (n=2,566), the most associated variants were classical HLA alleles, with HLA-DRB1*03:01 being the most significant 4-digit allele (p=2.58×10 −135 , OR=1.88, 95% CI=1.68-2.11). HLA-DRB1*03:01 forms part of the 8.1 AH which has been consistently associated with IIM. After conditioning on the effects of HLA-DRB1*03:01, a strong association was found with HLA-B*08:01 (p=3.23×10 −14 , OR=1.58, 95% CI=1.41-1.78) suggesting that there is an independent effect within this locus. Further residual associations highlight the heterogeneity within this cohort, so analysis was then conducted on clinical subgroups. Similar associations were found with PM (n=931), HLA-DRB1*03:01 being the most significant 4-digit allele (p=6.11×10 −80 , OR=1.99, 95% CI=1.67-2.36) and an independent effect with HLA-B*08:01 (p=4.17×10 −9 , OR=1.71, 95% CI=1.43-2.05). As the effect size of the HLA is strong in IIM, we hypothesised that we may be able to detect any potential differences between adult and juvenile DM, even with a reduced sample size. In adult DM (n=879), HLA-B*08:01 was the most significant allele (p=2.46×10 −42 , OR=1.90, 95% CI=1.66-2.17). Conditioning on HLA-B*08:01, there was evidence of multiple independent effects within the HLA-DQB1 locus, therefore we analysed imputed amino acid residues. Amino acid position 57 of HLA-DQB1 was more significantly associated with DM than individual HLA-DQB1 alleles (p=8.95×10 −14 ), with alanine (p=1.29×10 −12 OR=1.62, 95% CI=1.44-1.83) and serine (p=9.28×10 −7 , OR=2.15, 95% CI=1.60-2.84) conferring the greatest risk. Further association with HLA-DQB1 remains after conditioning, notably an independent effect of HLA-DQB1*04:02 (p=2.01×10 −6 , OR=1.99, 95% CI=1.52-2.58). In the JDM subgroup (n=481), HLA-DRB1*03:01 was the most associated allele (p=7.91×10 14 , OR=1.90, 95% CI=1.61-2.22) and an independent association was observed with HLA-C*02:02 (p=3.28×10 −7 , OR=1.99, 95% CI=1.55-2.52) which is not a part of the 8.1 ancestral haplotype.
Discussion
This is the largest genetic study to date in IIM, and has revealed several novel suggestive associations in adult and juvenile IIM emphasising the autoimmune architecture of these diseases. We have confirmed HLA and PTPN22 as the most strongly associated regions in IIM, and identified nine additional associations at a suggestive level of significance. Subgroup analysis has identified distinct differences between PM and DM. Identification of exonic and eQTL SNPs has localised association signals to several potential causal variants.
It is reassuring that associations such as PTPN22, STAT4 and UBE2L3 follow a similar genetic profile as reported in other autoimmune diseases. The most significantly associated SNP in the PTPN22 region is the rs2476601 variant, a C>T polymorphism that results in a non-synonymous arginine (R) to tryptophan (W) amino acid change at position 620. Although this SNP has been extensively studied in the context of autoimmunity, there is no consensus regarding the functional consequences of this SNP. Some studies report a gain of function mutation by enhancing the inhibitory effect on TCR signalling, [39] while others report a loss of function by increased degradation of the protein and a diminished inhibitory effect on T-cell activation. [40] STAT4 is an important transcription factor for many genes involved in T-cell differentiation and has previously been associated with DM in the Japanese population. [41] Stepwise logistic regression analysis was conducted on all regions in this study; however STAT4 is the only locus with evidence of independent associations. The three independent SNPs are in LD with associations in different diseases. The lead SNP in STAT4 is protective, and in moderate LD with protective SNPs in STAT4 reported in inflammatory bowel disease (IBD),
Crohn's and ulcerative colitis. [16] The independent risk effect of rs10174238 is the same SNP reported in juvenile idiopathic arthritis, [18] and is in strong LD with disease-associated SNPs in RA and SLE. [19, 42] A SNP in high LD with rs932169 has been reported to be associated with primary biliary cirrhosis. [25] The most significantly associated SNP in the YDJC gene tags an established autoimmune susceptibility locus where UBE2L3 is thought to be the causal gene. [43] This risk haplotype is thought to increase UBE2L3 expression in B cells and monocytes and amplify NF-κB activation. [43] Stratification by clinical subgroup revealed further novel suggestive associations. These distinct differences between PM and DM suggest different autoimmune pathways in these subsets of IIM. For example, when splitting the total IIM cohort into PM and DM, we have shown that the association with PTPN22 is predominantly driven by a strong association with PM. For all associations, we have stratified by clinical subgroup and reported the summary statistics in online supplementary Table S3 . IBM patients were included in the combined IIM analysis on the basis of their diagnosis as an inflammatory autoimmune myopathy, however we did not analyse this subgroup separately due to a lack of power (n=252). Removing this group from our analyses did not make any substantial difference in associated regions, however the strength of the signals were attenuated in most instances. With eight non-HLA loci reaching our level of suggestive significance in PM, and only 3 in DM, it may be that the Immunochip is explaining less of the genetic risk to DM. This may be due to lack of power, the selected content of the Immunochip, heterogeneity of phenotypes within DM, or a weaker genetic influence compared to other autoimmune diseases. Some previous reported associations with DM failed to replicate in this study. We looked for evidence of association with loci that have previously been associated with IIM that did not reach our suggestive level of significance. For example, in the DM and JDM subgroup analysis, an association was found with rs2618476 (p=3.2×10 −5 , OR=1.2, 95% CI=1.1-1.32), a SNP in B Lymphoid Tyrosine Kinase (BLK). rs2618476 is a proxy for a SNP that was associated with DM in the Japanese population, [44] and is also highly correlated (r 2 >0.8) with associations found in SLE and RA. [20, 29] With this knowledge, this association becomes more convincing, whereas the single association in the FAM167A-BLK region in the PM subgroup (rs17799348) that is independent of the established risk haplotype, is less so.
It is important to note that this study was conducted on Caucasian IIM individuals. While there is evidence that risk loci may be shared across populations, such as STAT4 and BLK in the Japanese population, the association between PTPN22 and autoimmune disease is unique to Caucasians as the R620W variant is rarely seen in Asian populations. There is therefore a need to conduct further genetic studies on different IIM populations.
The Immunochip contains a dense set of SNPs covering 186 loci based on evidence of association with 12 different autoimmune and inflammatory diseases. [18] IIM was not one of these diseases, so this study can be seen as an exploratory investigation to assess genetic overlap with other autoimmune diseases, rather than the identification of genes novel to IIM. With 2,566 samples, Immunochip studies of similar size have revealed multiple non-HLA associations reaching genome-wide significance. [18, 45] The fact that only a single locus reached this threshold may due to low statistical power owing to phenotypic heterogeneity within IIM. A more conservative level of significance (p<2.25×10 −5 ) revealed suggestive associations of interest. SNPs that are the same, or in high LD with established autoimmune variants, along with biological knowledge and/or evidence of functionality may lead us to pursue these associations with more confidence. Indeed, a recent Immunochip study in T1D calculated a Bayesian posterior probability of disease association >0.9 of SNPs reaching a suggestive level of significance (p<1×10 −5 ) when there is evidence of genome-wide significance in other Immunochip studies. [30] Due to the extended haplotypes that are present in the HLA region, for many associations, alleles carried on the same haplotype reached an equivalent significance level. For consistency, the most associated allele was used in the stepwise conditional analysis; however, this is not to say that the allele is causative. Interestingly in PM, two alleles frequently inherited together on the 8.1 AH (HLA-DRB1*03:01 and HLA-B*08:01) show evidence of having independent effects. This may also be the case in DM, however, after conditioning on HLA-B*08:01, the association with other alleles of the 8.1 AH did not reach genome-wide significance. In DM, the independent association with amino acid position 57 in HLA-DQB1 may explain part of the risk within this gene. Indeed, this position is an established risk factor for T1D. [46] In this study, classical 4-digit HLA alleles were preferentially reported, unless an amino acid association explained more risk than HLA alleles alone. However looking at amino acids may give insight into functionality. For example, the association with HLA-DRB1*03:01 may be explained by the presence of amino acids that are unique to that allele. An asparagine at position 77, and an arginine at position 74 also were highly associated with IIM (online supplementary Table S4 ), and these residues are predominantly found on DRB1*03 alleles. As there are multiple residues unique to this allele, it is hard to tease out which positions may be functionally important; however the location of these amino acids in the HLA-DRB1 molecule may give insight (online supplementary Figure S4 ). Amino acid position 74 of HLA-DRB1 lies within the peptide binding groove, and almost all of the risk at this position can be explained by the presence of an arginine (p=3.1×10 −72 , OR=2.83, 95% CI=2.53-3.17) . The location of Arg-74 may change the structure of the peptide binding groove in such a way as to accommodate autoantigenic peptides. Indeed Arg-74 is an established risk factor for the development of autoimmune diseases. [47] A similar phenomenon is seen with HLA-B*08:01 and the occurrence of Phe-67 and Asp-9 (online supplementary Figure S5 ).
Alleles of the 8.1 AH have frequently been associated with the presence of myositis autoantibodies such as anti-Jo-1 and anti-PM-Scl. It may be that the association with the 8.1 AH and IIM is due to the prevalence of these antibodies, and weak associations with other HLA-alleles may be due to associations with autoantibodies that are less frequent in the disease subgroup. Further work is planned to stratify patients by serotype to clarify these differences.
This study has revealed new suggestive associations with IIM in the Caucasian population, and independent associations with PM and DM. and has shown that subgrouping patients into clinical subgroups is important to expand our knowledge of IIM. This international collaboration has made it possible to perform the largest study to date in IIM and it has considerably expanded our knowledge about the genetic architecture of this rare disease.
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